Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer

Figure 1 Major growth factor receptor signalling pathways in HCC.

Figure 2 Antiproliferative effects of sorafenib-based combination treatment. A: Huh-7 and B: HEP-G2 cells were treated for 72 h with sub-IC₅₀ concentrations of sorafenib and the histone deactylase inhibitor MS-275. Combination of both agents resulted in synergistic growth inhibition of Huh-7 cells, while rather additive growth inhibitory effects were observed in HepP-G2 cells (mean ± SEM).

Figure 3 Antiproliferative effects of combination treatment with bortezomib and sorafenib in hepatocelluar carcinoma cells. A: Huh-7 and B: Hep-G2 cells were treated for 72 h with sub-IC₅₀ concentrations of sorafenib and the proteasome inhibitor bortezomib. Combination of both agents led to additive growth inhibition both in Huh-7 as well as in Hep-G2 cells (mean ± SEM).